Roman Butler Fullerton & Co. Invests $675,000 in Exelixis, Inc. $EXEL

Roman Butler Fullerton & Co. bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,277 shares of the biotechnology company’s stock, valued at approximately $675,000.

A number of other institutional investors have also recently made changes to their positions in EXEL. Sumitomo Mitsui Trust Group Inc. increased its stake in Exelixis by 0.5% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock worth $2,549,000 after acquiring an additional 281 shares during the last quarter. RHS Financial LLC lifted its stake in shares of Exelixis by 2.4% in the 4th quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock valued at $553,000 after purchasing an additional 293 shares during the last quarter. Meeder Advisory Services Inc. boosted its holdings in shares of Exelixis by 5.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock worth $237,000 after purchasing an additional 298 shares during the period. Cim LLC boosted its holdings in shares of Exelixis by 0.9% in the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock worth $1,462,000 after purchasing an additional 305 shares during the period. Finally, J.W. Cole Advisors Inc. increased its position in shares of Exelixis by 6.5% during the 4th quarter. J.W. Cole Advisors Inc. now owns 5,354 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 329 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In related news, EVP Patrick J. Haley sold 32,110 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total value of $1,599,399.10. Following the transaction, the executive vice president owned 357,638 shares of the company’s stock, valued at $17,813,948.78. This represents a 8.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack L. Wyszomierski sold 3,925 shares of Exelixis stock in a transaction on Monday, June 1st. The shares were sold at an average price of $50.55, for a total value of $198,408.75. Following the sale, the director directly owned 284,384 shares of the company’s stock, valued at approximately $14,375,611.20. This trade represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 219,170 shares of company stock valued at $10,620,641 in the last ninety days. Corporate insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EXEL. Stifel Nicolaus increased their price target on Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a report on Wednesday, May 6th. Barclays lifted their price objective on shares of Exelixis from $44.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Monday, April 20th. Morgan Stanley reiterated a “positive” rating on shares of Exelixis in a research report on Monday, June 22nd. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, HC Wainwright restated a “buy” rating and issued a $56.00 target price on shares of Exelixis in a report on Thursday, July 2nd. Nine research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $47.93.

Exelixis Trading Up 1.8%

NASDAQ EXEL opened at $57.10 on Friday. The stock has a market cap of $14.35 billion, a PE ratio of 18.97, a PEG ratio of 1.62 and a beta of 0.42. Exelixis, Inc. has a 12 month low of $33.76 and a 12 month high of $57.57. The company’s 50-day moving average price is $51.47 and its 200-day moving average price is $46.39.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. The company had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the business posted $0.55 EPS. As a group, sell-side analysts forecast that Exelixis, Inc. will post 3.16 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.